Prognosis
Novovax Gets WHO Nod for Covid Shot for Developing Countries
This article is for subscribers only.
The World Health Organization gave emergency-use status to a Covid-19 vaccine developed by Novavax Inc., the first protein-based shot to get approval against the virus.
The WHO said Friday the vaccine, known as Covovax, could be used globally and will help accelerate vaccination drives in lower-income countries. Covovax is a product based on Nuvaxovid, a vaccine made by Novavax that’s still under assessment by the European Medicines Agency. Novovax shares rose as much as 8.7%.